GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
17y agoen
From the article
GSK & GEN announced submission of BLA to the FD) for Arzerra to treat patients whose CLL is resistant (refractory) to previous therapies.
Continue reading on GSKYou might also wanna read
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
clinicaltrials.gov·7d ago
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
clinicaltrials.gov·8d ago
Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
clinicaltrials.gov·7d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·19d ago
EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment
The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine for metastatic pancreatic cancer. This acceler
ema.europa.eu·1d agoRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
clinicaltrials.gov·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.